Earnings Call Summary | InspireMD(NSPR.US) Q2 2024 Earnings Conference
Earnings Call Summary | InspireMD(NSPR.US) Q2 2024 Earnings Conference
The following is a summary of the InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript:
以下是InspireMD,Inc.(NSPR)2024年第二季度业绩会议通话记录摘要:
Financial Performance:
金融业绩:
InspireMD reported a quarterly revenue of $1.74 million, marking a growth of 5.4% from the same quarter last year.
Gross profit decreased by 32.6% to $331,000 due to increased material and labor costs, despite a slight increase in revenue.
Net loss for the quarter was $7,909,000, compared to a net loss of $5,077,000 in the second quarter of 2023.
InspireMD报告了174万美元的季度营业收入,同比去年同期增长5.4%。
由于材料和劳动成本增加,毛利润下降32.6%,尽管营业收入轻微增长。
本季度净亏损为790.9万美元,2023年第二季度净亏损为507.7万美元。
Business Progress:
业务进展:
InspireMD is preparing for the U.S. commercial launch of CGuard Prime, recruiting top talent and establishing a U.S. HQ in Southeast Florida.
The company presented positive one-year outcomes for the C-GUARDIANS clinical trial, supporting the efficacy of the CGuard Carotid Stent System.
They are anticipating FDA approval of CGuard Prime in the first half of 2025 and are preparing for significant commercial activities.
InspireMD正在为CGuard Prime的美国商业推出做准备,招募顶尖人才,在美国东南部建立总部。
公司公布了C-GUARDIANS临床试验一年的积极结果,支持CGuard颈动脉支架系统的功效。
他们预计CGuard Prime将于2025年上半年获得FDA批准,并为重要商业活动做准备。
Opportunities:
机会:
InspireMD's CGuard Carotid Stent System is set to potentially become the gold standard in carotid implants, bolstered by positive trial results and pending U.S. approval.
Expansion into the U.S. market could significantly increase revenue given the higher procedure rates and reimbursement levels compared to current markets.
InspireMD的CGuard颈动脉支架系统有望成为颈动脉植入物的黄金标准,受到积极试验结果和即将获得的美国批准的支持。
进军美国市场可能会显著增加营业收入,因为相比目前市场,美国市场的手术率和补偿水平更高。
Risks:
风险:
The ongoing investment in clinical trials such as C-GUARDIANS II and III could increase operating expenses significantly, impacting financial stability.
持续投资于C-GUARDIANS II和III等临床试验可能会显著增加营业费用,影响财务稳定性。
More details: InspireMD IR
更多详细信息:InspireMD IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由AI生成。文章内容的准确性无法完全保证。有关更全面的详细信息,请参阅IR网站。本文只是为投资者提供参考,没有任何指导或推荐建议。